Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement?

Interactive Cardiovascular and Thoracic Surgery

Volumn 5, Issue 5, 2006, Pages 616-623

  El Husseiny, Moataz ^a   Salhiyyah, Kareem ^a   Raja, Shahzad G ^a   Dunning, Joel ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anticoagulants; Aortic valve; Bioprosthesis; Mitral valve; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; VITAMIN K GROUP; WARFARIN;

ADULT; ARTICLE; CASE REPORT; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; PRIORITY JOURNAL; PUBLICATION; SURGEON; THROMBOEMBOLISM;

EID: 33749420165     PISSN: 15699293     EISSN: 15699293     Source Type: Journal    
DOI: 10.1510/icvts.2006.136234     Document Type: Article

References (18)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact Cardiovasc Thorac Surg 2003;2:405-409.
2. Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, Hall RJ, Vahanian A. Working groups on valvular heart disease, thrombosis, and cardiac rehabilitation and exercise physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26:2463-2471.
3. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220S-227S.
4. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:457S-482S.
5. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. ACC/AHA Guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on management of patients with valvular heart disease). J Heart Valve Dis 1998;7:672-707.
6. Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on management of patients with valvular heart disease). Circulation 1998;98:1949-1984.
7. Lowe G, Belch J, Burton C, Cachia P, Cook M, Cooke T, Forbes C, Greer I, Irving J, Ludlam C, McInnes G, Murray P, Sandercock P, Treasure I, Walker I, Webster J. Antithrombotic therapy. Scottish Intercollegiate Guidelines Network (SIGN), 1999..
8. British Society of Haematologists. Guidelines on oral anticoagulation: Third edition. Br J Haematol 1998;101:374-387.
9. CTSNet editors. Valve technology center. Anticoagulation therapy after aortic tissue valve replacement. The Cardiothoracic Surgery Network (CTSNet), 2004.
10. Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis 2005;14:576-582.
11. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, Puga FJ, Orszulak TA, Schaff HV. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 2005;129:1024-1031.
12. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D'Amico R, Beghi C. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 2004;110:496-500.
13. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, Schaff HV, Larsonkeller JJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119.
14. Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G, Elefteriades J. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation 1998;98:II95-98; discussion II98-99.
15. Mistiaen W, Van Cauwelaert P, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 2004;127:1166-1170.
16. Yao H, Miyamoto T, Mukai S, Yamamura M, Tanaka H, Nakagawa T, Ryomoto M, Inai Y, Yoshioka Y, Kaji M. Long-term results of mitral valve replacement: biological xenograft versus mechanical valves. J Artif Organs 2003;6:30-36.
17. Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-1245.
18. Ionescu MI, Smith DR, Hasan SS, Chidambaram M, Tandon AP. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement. Ann Thorac Surg 1982;34:265-277.